Aviso: Este sitio agrega datos públicos oficiales de la FDA, ClinicalTrials.gov, PubMed y SEC EDGAR solo como referencia general. No constituye asesoramiento médico, diagnóstico, recomendaciones de tratamiento ni asesoramiento de inversión.

PubMed

Orbital Implants Receiving Food and Drug Administration Premarket Notification.

PMID: 35699217 ·

K, i, a, r, a, , M, , C, o, r, c, o, r, a, n, , R, u, i, z, ;, , Y, a, s, h, , J, , V, a, i, s, h, n, a, v, ;, , J, o, r, d, a, n, , D, e, s, a, u, t, e, l, s, ;, , J, a, m, i, e, , L, , S, c, h, a, e, f, e, r, ;, , M, i, c, h, a, e, l, , E, , M, i, g, l, i, o, r, i, ;, , T, a, y, g, a, n, , Y, i, l, m, a, z

RevistaOphthalmic plastic and reconstructive surgery
Año
PMID35699217

Resumen

This perspective explores the Food and Drug Administration (FDA) 510(k) program, occasionally referred to as premarket notification, which facilitates faster marketing of Class II medical devices, such as orbital implants by demonstrating "substantial equivalence" to previously approved devices. This allows for FDA clearance, rather than FDA approval of orbital implants via comparison to currently marketed implants rather than clinically proven safety standards. Utilizing the FDA's publicly avai

Fuente oficial

Ver en PubMed →

Datos obtenidos de PubMed / NCBI. Para consultar el texto completo y la información más reciente, remítase siempre al registro oficial.

↑